# DESCRIPTION

## BACKGROUND OF THE INVENTION

- describe retinal structure and function
- discuss retinal diseases and need for treatment

## BRIEF SUMMARY OF THE INVENTION

- introduce method of treating retinal disease
- describe compounds and their effects
- specify retinal diseases to be treated
- outline pharmaceutical compositions
- mention administration methods

## DETAILED DESCRIPTION OF THE INVENTION

- define terms and conventions
- describe scope of disclosure
- explain transitional phrases
- define specific terms
- introduce therapeutic compounds
- define biological molecules
- describe compounds of the invention
- outline therapeutic compositions
- describe pharmaceutical compositions
- outline administration routes
- describe ophthalmic pharmaceutical compositions
- list additives for eye drops
- describe pharmaceutical compositions
- formulate injectable preparations
- formulate oral dosage forms
- formulate suppositories for rectal administration
- formulate topical preparations
- administer pharmaceutical compositions
- describe therapeutic methods
- treat ophthalmic diseases
- treat retinal degradation
- restore retinal pigment epithelium cells
- provide kits for administration

## EXAMPLES

### Example 1—Complement Competent Human Serum (CC-HS) Induces AMD-Like Cellular Endophenotypes in Mature iPSC-RPE

- induce AMD-like cellular endophenotypes
- characterize RPE cell-autonomous pathways

### Example 2—CC-HS Triggered AMD Disease Phenotypes are Induced Through C3aR1 and C5aR1 Signaling

- investigate C3aR1 and C5aR1 signaling

### Example 3—C3aR1 and C5aR1 Induced subRPE Deposits are Mediated by Overactivation of NF-KB and Downregulation of Autophagy Pathways

- analyze global gene expression pattern
- investigate NF-KB and autophagy pathways
- confirm role of NF-KB and autophagy in AMD disease phenotypes

### Example 4—High Throughput Screen to Discover iRPE Cytoprotective Drugs

- design and perform high-throughput screen

### Example 5—L456,780 and Aminocaproic Acid Reversed CC-HS Induced NF-kB Activation and Autophagy Suppression in iRPE Cells

- test cytoprotective drugs on iRPE cells

### Example 6—Restoration of iRPE Epithelial Phenotype In Vitro in CC-HS Treated Cells and In Vivo in a Rat Model

- demonstrate restoration of iRPE epithelial phenotype

### Example 7—Mechanism of L-ORD and AMD and Use of Metformin as an Effective Therapy

- introduce L-ORD and AMD disease models
- generate patient-specific iPSCs and differentiate into RPE
- verify iPSC-RPE model recapitulates human disease phenotype
- investigate relationship between CTRP5 mutation and disease-causing phenotypes
- identify CTRP5 as autocrine regulator of RPE metabolism
- determine CTRP5 fine-tunes AMPK sensitivity to cell energy status
- investigate how AMPK defect contributes to disease pathogenesis in L-ORD
- evaluate PEDF-R mediated retinal neuroprotection in L-ORD patients
- demonstrate metformin resensitizes AMPK and reverses pathological phenotype
- provide clinical evidence for metformin as a potential treatment for dry AMD

### Example 8—Analysis of iPSC-RPE from Patients with Late-Onset Retinal Degeneration Identifies the Role of AMPK in Regulating Healthy RPE Phenotype and LED to a Re-Purposing of Metformin, a Known Type 2 Diabetes Drug for a Potential Treatment of AMD and Other Retinal Degenerative Diseases

- describe L-ORD pathology and genetic basis
- demonstrate metformin treatment effects on AMPK signaling and RPE phenotype

### Example 9—Metformin Delays Median-Age of Onset for Retinal Degenerative Diseases

- introduce metformin as a treatment for type 2 diabetes
- describe retrospective cohort study of patients with AMD
- present results of study, including delayed age of onset
- describe iPSC-RPE cell culture and testing methods
- present data on expression and localization of CTRP5 in L-ORD patient-derived RPE
- describe altered AMPK signaling and lipid metabolism in L-ORD patients
- present data on increased susceptibility to epithelial-mesenchymal transition in L-ORD patient RPE
- summarize results of study, including delayed age of onset of AMD with metformin treatment
- introduce Stargardt disease
- describe ABCA4's role in RPE and disease pathogenesis
- develop Stargardt iPSC-derived RPE model
- investigate ABCA4's role in lipid metabolism
- test metformin's therapeutic effect on Stargardt iRPE cells
- evaluate metformin's therapeutic effect in Abca4−/− mouse model
- describe POS digestion defect in Stargardt iRPE cells
- confirm efficacy of treatment using various administration methods

## EQUIVALENTS

- define equivalents

